Switch theme
Sign up to access all valuation multiples
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its products include Paltusotine and Atumelnant.
2008
437
LTM Revenue $2.9M
LTM EBITDA -$396M
$1.6B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Crinetics Pharmaceuticals has a last 12-month revenue (LTM) of $2.9M and a last 12-month EBITDA of -$396M.
In the most recent fiscal year, Crinetics Pharmaceuticals achieved revenue of $1.0M and an EBITDA of -$336M.
Crinetics Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Crinetics Pharmaceuticals valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $2.9M | XXX | $1.0M | XXX | XXX | XXX |
| Gross Profit | $2.7M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 94% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$396M | XXX | -$336M | XXX | XXX | XXX |
| EBITDA Margin | -13603% | XXX | -32345% | XXX | XXX | XXX |
| EBIT | -$402M | XXX | -$339M | XXX | XXX | XXX |
| EBIT Margin | -13787% | XXX | -32613% | XXX | XXX | XXX |
| Net Profit | -$359M | XXX | -$298M | XXX | XXX | XXX |
| Net Margin | -12327% | XXX | -28721% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of June 23, 2025, Crinetics Pharmaceuticals's stock price is $30.
Crinetics Pharmaceuticals has current market cap of $2.8B, and EV of $1.6B.
See Crinetics Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.6B | $2.8B | XXX | XXX | XXX | XXX | $-4.08 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of June 23, 2025, Crinetics Pharmaceuticals has market cap of $2.8B and EV of $1.6B.
Crinetics Pharmaceuticals's trades at 1542.0x EV/Revenue multiple, and -4.8x EV/EBITDA.
Equity research analysts estimate Crinetics Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Crinetics Pharmaceuticals has a P/E ratio of -7.9x.
See valuation multiples for Crinetics Pharmaceuticals and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2.8B | XXX | $2.8B | XXX | XXX | XXX |
| EV (current) | $1.6B | XXX | $1.6B | XXX | XXX | XXX |
| EV/Revenue | 550.1x | XXX | 1542.0x | XXX | XXX | XXX |
| EV/EBITDA | -4.0x | XXX | -4.8x | XXX | XXX | XXX |
| EV/EBIT | -4.0x | XXX | -4.7x | XXX | XXX | XXX |
| EV/Gross Profit | 584.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | -7.9x | XXX | -9.5x | XXX | XXX | XXX |
| EV/FCF | -5.0x | XXX | -7.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialCrinetics Pharmaceuticals's last 12 month revenue growth is 717%
Crinetics Pharmaceuticals's revenue per employee in the last FY averaged $2K, while opex per employee averaged $0.8M for the same period.
Crinetics Pharmaceuticals's rule of 40 is -4803% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Crinetics Pharmaceuticals's rule of X is -11810% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Crinetics Pharmaceuticals and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 717% | XXX | 556% | XXX | XXX | XXX |
| EBITDA Margin | -13603% | XXX | -32345% | XXX | XXX | XXX |
| EBITDA Growth | 17% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -4803% | XXX | -31628% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -11810% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $2K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.8M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 23114% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 32713% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Crinetics Pharmaceuticals acquired XXX companies to date.
Last acquisition by Crinetics Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Crinetics Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Crinetics Pharmaceuticals founded? | Crinetics Pharmaceuticals was founded in 2008. |
| Where is Crinetics Pharmaceuticals headquartered? | Crinetics Pharmaceuticals is headquartered in United States of America. |
| How many employees does Crinetics Pharmaceuticals have? | As of today, Crinetics Pharmaceuticals has 437 employees. |
| Who is the CEO of Crinetics Pharmaceuticals? | Crinetics Pharmaceuticals's CEO is Dr. R. Scott Struthers, PhD. |
| Is Crinetics Pharmaceuticals publicy listed? | Yes, Crinetics Pharmaceuticals is a public company listed on NAS. |
| What is the stock symbol of Crinetics Pharmaceuticals? | Crinetics Pharmaceuticals trades under CRNX ticker. |
| When did Crinetics Pharmaceuticals go public? | Crinetics Pharmaceuticals went public in 2018. |
| Who are competitors of Crinetics Pharmaceuticals? | Similar companies to Crinetics Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Crinetics Pharmaceuticals? | Crinetics Pharmaceuticals's current market cap is $2.8B |
| What is the current revenue of Crinetics Pharmaceuticals? | Crinetics Pharmaceuticals's last 12 months revenue is $2.9M. |
| What is the current revenue growth of Crinetics Pharmaceuticals? | Crinetics Pharmaceuticals revenue growth (NTM/LTM) is 717%. |
| What is the current EV/Revenue multiple of Crinetics Pharmaceuticals? | Current revenue multiple of Crinetics Pharmaceuticals is 550.1x. |
| Is Crinetics Pharmaceuticals profitable? | Yes, Crinetics Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Crinetics Pharmaceuticals? | Crinetics Pharmaceuticals's last 12 months EBITDA is -$396M. |
| What is Crinetics Pharmaceuticals's EBITDA margin? | Crinetics Pharmaceuticals's last 12 months EBITDA margin is -13603%. |
| What is the current EV/EBITDA multiple of Crinetics Pharmaceuticals? | Current EBITDA multiple of Crinetics Pharmaceuticals is -4.0x. |
| What is the current FCF of Crinetics Pharmaceuticals? | Crinetics Pharmaceuticals's last 12 months FCF is -$321M. |
| What is Crinetics Pharmaceuticals's FCF margin? | Crinetics Pharmaceuticals's last 12 months FCF margin is -11014%. |
| What is the current EV/FCF multiple of Crinetics Pharmaceuticals? | Current FCF multiple of Crinetics Pharmaceuticals is -5.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
